US Stock MarketDetailed Quotes

FOLD Amicus Therapeutics

Watchlist
  • 9.230
  • -0.250-2.64%
Close May 10 16:00 ET
  • 9.230
  • 0.0000.00%
Post 16:20 ET
2.73BMarket Cap-18836P/E (TTM)

About Amicus Therapeutics Company

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Company Profile

SymbolFOLD
Company NameAmicus Therapeutics
Listing DateMay 31, 2007
Issue Price15.00
Founded2002
CEOMr. Bradley L. Campbell
MarketNASDAQ
Employees517
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address47 Hulfish Street
CityPrinceton
ProvinceNew Jersey
CountryUnited States of America
Zip Code08542
Phone1-609-662-2000

Company Executives

  • Name
  • Position
  • Salary
  • Bradley L. Campbell
  • Director, President and Chief Executive Officer
  • 8.20M
  • David M. Clark
  • Chief People Officer
  • 3.21M
  • Ellen S. Rosenberg
  • Chief Legal Officer, General Counsel and Corporate Secretary
  • 4.08M
  • Simon Nicolas Reade Harford
  • Chief Financial Officer
  • 2.98M
  • Samantha Prout
  • Chief Accounting Officer and Controller
  • --
  • Jeffrey P. Castelli
  • Chief Development Officer
  • 3.67M
  • Michael G. Raab
  • Lead Independent Director and Chairman of the Board
  • 426.25K
  • Margaret G. McGlynn
  • Independent Director
  • 401.25K
  • Dr. Eiry W. Roberts, M.D.
  • Independent Director
  • 390.00K
  • Lynn Dorsey Bleil
  • Independent Director
  • 397.50K
  • Glenn P. Sblendorio
  • Independent Director
  • 407.07K
  • Craig A. Wheeler
  • Independent Director
  • 398.50K
  • Burke W. Whitman
  • Independent Director
  • 391.25K
  • Michael A Kelly
  • Independent Director
  • 391.25K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg